Technology | November 14, 2011

Everist Genomics Offers Real-Time Heart Monitoring Smartphone Software

November 14, 2011 — Everist Genomics announced plans to commercialize its CardioDefender diagnostic system. It is the first U.S. Food and Drug Administration (FDA)-approved and CE mark-registered smartphone echocardiogram (ECG) system to provide hospital-quality heart rhythm monitoring outside of the hospital setting. The system incorporates several capabilities enabling physicians to diagnose and treat potentially life-threatening arrhythmias that might otherwise be missed.

CardioDefender is the first system to deliver mobile, real-time, beat-by-beat, and quantitative heart monitoring and automated reporting by combining patented analytical smartphone software with a Bluetooth device and electrodes. The electrodes—which are attached to the patient's skin—transmit heart rhythm data to the Bluetooth device, which then transmits it to the smartphone. The software analyzes the data, which data is sent to a cardiac monitoring center; the center keeps an encrypted record of the data that can be reviewed by physicians.

Physicians are also able to receive arrhythmia alerts via their smartphone, tablet, laptop or desktop computer. In the event of a significant arrhythmia, the system will automatically transmit an alert to the patient's physician while the event is occurring.

The Joint Committee of the American Heart Association/American College of Cardiology (AHA/ACC) recommends everyone over 40 years of age should be examined for potential heart arrhythmias. In the United States alone, more than 4 million people a year suffer from recurrent arrhythmias warranting a physician's care. About 780,000 people are admitted to the hospital for arrhythmias annually.

Arrhythmias are a very common event—almost everyone occasionally experiences minor arrhythmias that don't require medical attention. In contrast to these benign cases, however, some arrhythmias result in sudden cardiac death (SCD). In fact, most cases of SCD are caused by a specific type of arrhythmia known as ventricular fibrillation.

Ventricular fibrillation accounts for 75-80 percent of all SCDs in the United States. This type of arrhythmia also is often the first expression of coronary artery disease (CAD). It is responsible for approximately 50 percent of deaths from CAD, often within the first hour after the onset of a heart attack or coronary syndrome.

Identifying patients at risk of ventricular fibrillation remains a significant challenge. Although research shows the risk of ventricular fibrillation is greater among people with a history of cardiac events, only a small percentage of total ventricular fibrillation events actually occur in these patients. Identification of other types of heart arrhythmias also represents a major challenge as many arrhythmias occur without any signs or symptoms.

Conventional methods for monitoring and diagnosing arrhythmias have included hospital-based ECG systems, portable ECG recorders and Holter monitors, each of which present significant limitations. Hospital-based ECG monitoring, for example, typically limits the observation period to a few days, despite the fact people with intermittent arrhythmias rarely experience them at the hospital or doctor's office.

On the other hand, ECG recorders and Holters enable physicians to monitor patients' heart rhythm data remotely; such devices do not provide real-time, beat-by-beat, quantitative heart rhythm monitoring.

Moreover, portable ECG recorders and Holters are generally limited to less than 4 hours or 6 events of actual event recording time. Furthermore, these devices cannot simultaneously transmit heart rhythm data to monitoring centers while recording new data.

Following FDA approval and European CE Mark registration last year, CardioDefender has already been deployed at more than 150 medical facilities in the United States for post-approval commercial evaluation. Between January and October of this year, the number of patient days of heart rhythm monitoring performed with CardioDefender grew from fewer than 5,000 to more than 18,000 patient days per month.

This novel diagnostic system complements the AngioDefender diagnostic device for assessing endothelial function.

The company plans to make the CardioDefender system commercially available to international markets in January 2012.

For more information: www.everistgenomics.com

Related Content

HeartSciences has been developing a new type of ECG system called Wavelet ECG that may offer a new way of looking at the heart. The MyoVista system uses continuous wavelet transform (CWT) signal processing to provide new frequency and energy information to detect cardiac relaxation abnormalities associated with left ventricular diastolic dysfunction commonly associated with hypertension, diabetes, valvular disease, ischemia, and reduced systolic function. Artificial intelligence is used to read the exam.

HeartSciences has been developing a new type of ECG system called Wavelet ECG that may offer a new way of looking at the heart. The MyoVista system uses continuous wavelet transform (CWT) signal processing to provide new frequency and energy information to detect cardiac relaxation abnormalities associated with left ventricular diastolic dysfunction commonly associated with hypertension, diabetes, valvular disease, ischemia and reduced systolic function. Artificial intelligence is used to read the nuances of these complex waveforms.

Feature | ECG | January 20, 2021 | By Dave Fornell, Editor
Here are a few trends to watch for in electrocardiogram (ECG, or if you prefer the original German EKG) systems.
OTC ECG devices

OTC ECG devices can help detect abnormal heart rhythms in the general population, and this technology will continue to improve.

Feature | ECG | March 11, 2020
Apple created a stir when it...
Several wearable, less-obtrusive ECG monitors fhave been cleared by the FDA for longer wear. This example is Cardiac Insight’s Cardea SOLO device. 

Several wearable, less-obtrusive ECG monitors have been cleared by the FDA for longer wear. This example is Cardiac Insight’s Cardea SOLO device. 

Feature | ECG | February 19, 2020
When the patients of Michael Boler, M.D. need cardiac monitoring, the Holter monitor is no longer his first choice. “...
The Bittium Faros uses a 4-in-1 ECG technology. It is a lightweight, waterproof and can be configured for different patient monitoring needs. Bittium Faros Holter monitoring.

The Bittium Faros uses a 4-in-1 ECG technology. It is a lightweight, waterproof and can be configured for different patient monitoring needs. 
 

News | ECG | January 22, 2020
January 22, 2020 – Bittium is exhibiting solutions for cardiology at...
Cardiologs
News | ECG | December 12, 2019
December 12, 2019 — Cardiologs, a global leader in artificial intelligence (AI)
FDA Clears AliveCor's KardiaMobile 6L as First Six-Lead Personal ECG Device
Technology | ECG | May 13, 2019
AliveCor announced its third U.S. Food and Drug Administration (FDA) clearance in three months, making KardiaMobile 6L...
One innovation in ECG is its use in the customer wearable market, which will tie more closely into the clinical world either with using the data to triage patients and/or patients seeking medical attention prior to acute symptoms appearing.

One innovation in ECG is its use in the customer wearable market, which will tie more closely into the clinical world either with using the data to triage patients and/or patients seeking medical attention prior to acute symptoms appearing.

Feature | ECG | May 03, 2019 | Sanket Solanki
Technology has made its way into the healthcare sector and brought a drastic transformation.
Videos | ECG | March 05, 2019
This is a quick demo of the Schiller Cardiovit FT-1 electrocardiograph (ECG) system displayed at the ...
EKG With Artificial Intelligence Reliably Detects Heart Failure Precursor
News | ECG | January 08, 2019
January 8, 2019 — A Mayo Clinic study finds that applying...
Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use an adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer.

Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use a small, adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer. 

Feature | ECG | September 27, 2018
Advances in the technology of wearable cardiac monitors are improving both the experience of the patient and the effe